Using a pooled in vivo genetic screening approach utilizing CRISPR-Cas9 genome editing in transplantable B16 melanoma tumors in mice treated with anti-PD-1 therapy, Manguso and colleagues identified ADAR1 as a top candidate to boost cancer immunotherapy [148]. The gene discussed is ADAR; the disease is melanoma.